^
BIOMARKER:

CD8 expression

i
Other names: CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
Entrez ID:
Related biomarkers:
Phase 2
John L. Villano, MD, PhD
Recruiting
Last update posted :
06/14/2021
Initiation :
10/26/2017
Primary completion :
12/01/2022
Completion :
06/30/2028
PD-L1 • CD8 • PD-1 • CD4
|
PD-L1 expression • CD8 expression
|
Opdivo (nivolumab)
Phase 1
Jonsson Comprehensive Cancer Center
Recruiting
Last update posted :
06/10/2021
Initiation :
12/05/2018
Primary completion :
06/30/2022
Completion :
06/30/2023
PD-L1 • CD8 • PD-1 • CD4
|
PD-L1 expression • EGFR mutation • EGFR T790M • ALK rearrangement • CD8 expression
|
Keytruda (pembrolizumab) • Ad-CCL21-DC
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
06/09/2021
Initiation :
01/26/2018
Primary completion :
01/23/2022
Completion :
01/23/2022
CD8 • CD4
|
PD-L1 expression • CD8 expression • CD4 expression
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CMAB 819 (nivolumab biosimilar)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
06/09/2021
Initiation :
07/17/2017
Primary completion :
03/15/2022
Completion :
03/15/2022
CD8 • CD4
|
CD8 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • CMAB 819 (nivolumab biosimilar) • CS1002 (ipilimumab biosimilar)
Phase N/A
Lawson Health Research Institute
Not yet recruiting
Last update posted :
06/07/2021
Initiation :
08/01/2021
Primary completion :
08/01/2023
Completion :
08/01/2024
PD-L1 • CD8 • CEACAM5
|
PD-L1 expression • CD8 expression • CEACAM5 expression
Phase 1
Hoffmann-La Roche
Recruiting
Last update posted :
05/26/2021
Initiation :
08/13/2019
Primary completion :
01/05/2023
Completion :
01/05/2023
CD20 • CD8 • CD19
|
CD20 expression • CD8 expression • CD19 expression
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RO7227166 • glofitamab (RG6026)
Phase 2
Hoffmann-La Roche
Recruiting
Last update posted :
05/20/2021
Initiation :
06/18/2021
Primary completion :
08/20/2024
Completion :
08/20/2024
CD8 • PD-1 • LAG3 • HAVCR2 • CD4
|
CD8 expression • LAG3 expression
|
Opdivo (nivolumab) • RO7121661 • RO7247669
Phase 1
University of Colorado, Denver
Active, not recruiting
Last update posted :
05/20/2021
Initiation :
11/01/2018
Primary completion :
05/19/2021
Completion :
05/19/2022
CD8 • PD-1
|
PD-1 expression • CD8 expression • CDKN2A negative
|
Imfinzi (durvalumab)
Phase 2
Institut du Cancer de Montpellier - Val d'Aurelle
Active, not recruiting
Last update posted :
05/19/2021
Initiation :
07/15/2017
Primary completion :
07/01/2022
Completion :
07/01/2022
CD8 • PD-1 • CD73 • HAVCR2 • CD4 • ENTPD1
|
PD-1 expression • CD8 expression
|
cisplatin
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/05/2021
Initiation :
10/02/2017
Primary completion :
06/30/2023
Completion :
06/30/2023
CD8
|
CD8 expression
|
Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)
Phase 1
Fred Hutchinson Cancer Research Center
Recruiting
Last update posted :
04/05/2021
Initiation :
11/03/2017
Primary completion :
12/31/2021
Completion :
12/31/2022
BCL2 • CD20 • CD8 • BCL6 • CD19 • CD4
|
CD19 positive • CD8 expression • BCL2 rearrangement • BCL6 rearrangement • CD19 expression • CD4 expression
|
cyclophosphamide intravenous • fludarabine IV • JCAR014
Phase N/A
Yu Yao, MD
Recruiting
Last update posted :
03/24/2021
Initiation :
03/10/2021
Primary completion :
09/30/2022
Completion :
09/30/2022
PD-L1 • TMB • CD8 • PD-1 • TERT • CD4
|
PD-L1 expression • CD8 expression • TERT mutation
Phase 2
Novartis Pharmaceuticals
Recruiting
Last update posted :
02/26/2021
Initiation :
09/10/2018
Primary completion :
12/10/2021
Completion :
06/24/2022
CD8 • LAG3
|
CD8 expression
|
Kisqali (ribociclib) • spartalizumab (PDR001) • Tabrecta (capmatinib) • Ilaris (canakinumab) • ieramilimab (LAG525)
Phase 2
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
02/24/2021
Initiation :
04/20/2016
Primary completion :
02/16/2021
Completion :
02/17/2021
PD-L1 • CD8 • IFNG • IL6 • TNFA • CD4
|
PD-L1 expression • CD8 expression
|
spartalizumab (PDR001)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/26/2021
Initiation :
06/28/2014
Primary completion :
04/06/2017
Completion :
02/28/2018
CD8 • IFNG • TNFA • IL2 • CD27 • IL10 • CD40LG • ICAM1 • IL4 • LAMP1
|
EGFR mutation • ER positive • CD8 expression
|
BN-Brachyury
Phase 2
Medical University of South Carolina
Active, not recruiting
Last update posted :
01/08/2021
Initiation :
05/30/2017
Primary completion :
07/01/2021
Completion :
12/01/2021
CD8 • IL2 • GZMB • IL10 • TGFB1 • CD4 • ICOS • FOXP3 • CD69
|
CD8 expression • IL2 expression
|
Opdivo (nivolumab)
Phase 
Poitiers University Hospital
Not yet recruiting
Last update posted :
11/26/2020
Initiation :
11/01/2020
Primary completion :
11/01/2022
Completion :
11/01/2027
CD8 • IFNG • IL2RA • CCR7 • ITGA4
|
CD8 expression • IFNG expression
Phase 1
Yvonne Saenger
Active, not recruiting
Last update posted :
11/13/2020
Initiation :
10/01/2015
Primary completion :
11/01/2022
Completion :
11/01/2024
CD8 • PD-1 • PD-L2 • CD2
|
CD8 expression
|
Keytruda (pembrolizumab)
Phase N/A
Institut Claudius Regaud
Recruiting
Last update posted :
11/06/2020
Initiation :
01/17/2020
Primary completion :
09/01/2029
Completion :
09/01/2029
PD-1 • CD4
|
CD8 expression
Phase 1/2
University of Alabama at Birmingham
Recruiting
Last update posted :
10/09/2020
Initiation :
10/01/2020
Primary completion :
08/01/2022
Completion :
08/01/2022
BCL2 • ATM • CCND1 • CD8 • RAD51 • CASP3 • CHEK1 • IL10 • CD4 • IL22 • FOXP3 • PCNA
|
BCL2 expression • CD8 expression • CCND1 expression • CD4 expression • FOXP3 expression • PCNA expression
|
UAB30
Phase 1b
Pfizer
Completed
Last update posted :
09/04/2020
Initiation :
09/08/2017
Primary completion :
08/27/2019
Completion :
10/25/2019
PD-L1 • CD8
|
CD8 expression
|
Bavencio (avelumab) • Inlyta (axitinib)
Phase N/A
South Egypt Cancer Institute
Completed
Last update posted :
08/21/2020
Initiation :
04/15/2018
Primary completion :
06/01/2020
Completion :
08/01/2020
CD8 • NCAM1 • VEGFC
|
CD8 expression
Phase 2
Merck Sharp & Dohme Corp.
Terminated
Last update posted :
07/15/2020
Initiation :
06/28/2018
Primary completion :
08/14/2019
Completion :
08/14/2019
BRAF • CD8
|
BRAF mutation • CD8 expression
|
Keytruda (pembrolizumab)
Phase 3
Pfizer
Terminated
Last update posted :
07/14/2020
Initiation :
05/19/2016
Primary completion :
09/07/2018
Completion :
05/16/2019
PD-L1 • CD8 • MUC16
|
PD-L1 expression • CD8 expression • CD8 positive • MUC16 elevation • CD8 negative
|
carboplatin • paclitaxel • Bavencio (avelumab)
Phase 1
Aduro Biotech, Inc.
Active, not recruiting
Last update posted :
07/09/2020
Initiation :
04/28/2016
Primary completion :
02/01/2021
Completion :
02/01/2021
CD8 • IFNG
|
CD8 expression • IFNG expression
|
Yervoy (ipilimumab) • ADU-S100
Phase 
Shanghai Pulmonary Hospital, Shanghai, China
Not yet recruiting
Last update posted :
04/21/2020
Initiation :
06/01/2020
Primary completion :
12/31/2022
Completion :
05/31/2023
CD8 • IL6 • CXCL8 • TNFA • CXCL10 • IL2 • CCL2 • CSF2 • IL10 • CD4 • CD69 • IL4
|
CD8 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab)
Phase 1/2
University Children's Hospital Tuebingen
Active, not recruiting
Last update posted :
03/26/2020
Initiation :
06/01/2016
Primary completion :
03/01/2021
Completion :
08/01/2021
CD8 • CD4
|
CD8 expression • CD4 expression
|
Zyclara (imiquimod)
Phase 1
Peking University
Completed
Last update posted :
06/21/2019
Initiation :
04/06/2017
Primary completion :
12/11/2018
Completion :
05/11/2019
PD-L1 • CD8
|
PD-L1 expression • CD8 expression
|
Tuoyi (toripalimab)
Phase N/A
Sichuan University
Active, not recruiting
Last update posted :
01/21/2019
Initiation :
10/01/2016
Primary completion :
12/01/2019
Completion :
12/01/2019
PD-L1 • CD8 • PD-1 • CD4
|
PD-L1 expression • PD-1 expression • CD8 expression
|
cisplatin
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/11/2019
Initiation :
03/01/2004
Primary completion :
11/12/2010
Completion :
01/09/2019
CD8 • IL2 • CD22
|
CD8 expression
|
Hu-Mik-Beta-1
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
10/11/2018
Initiation :
07/16/2009
Primary completion :
07/31/2017
Completion :
07/31/2017
CD8 • PD-1 • HAVCR2
|
CD8 expression • HAVCR2 expression
|
Avastin (bevacizumab) • Revlimid (lenalidomide) • docetaxel • prednisone
Phase 2
Fred Hutchinson Cancer Research Center
Completed
Last update posted :
06/08/2018
Initiation :
09/13/2013
Primary completion :
10/31/2016
Completion :
05/18/2017
BRAF • CD8 • IFNG • IDO1 • CTLA4 • CD4
|
BRAF V600E • BRAF V600 • CD8 expression • IDO1 expression
|
epacadostat (INCB024360)
Phase 2
Nina Bhardwaj
Completed
Last update posted :
02/13/2018
Initiation :
09/01/2010
Primary completion :
03/11/2013
Completion :
03/11/2013
CD8 • CTAG1B • CD4
|
CD8 expression • CTAG1B expression
|
Hiltonol (poly-ICLC)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/29/2018
Initiation :
01/05/2012
Primary completion :
03/03/2016
Completion :
09/01/2016
CD8 • TNFA • IL2 • CD27 • CD4 • CD40LG • LAMP1
|
ER positive • CD8 expression
|
GI-6301
Phase 1/2
National Cancer Institute (NCI)
Terminated
Last update posted :
08/10/2017
Initiation :
03/04/2010
Primary completion :
10/21/2015
Completion :
10/21/2015
CD8 • HAVCR2
|
CD8 expression
|
cisplatin • doxorubicin hydrochloride • cyclophosphamide intravenous • Beleodaq (belinostat)
Phase 2
Fred Hutchinson Cancer Research Center
Completed
Last update posted :
05/17/2017
Initiation :
01/01/2002
Primary completion :
03/01/2011
Completion :
02/01/2014
CD8 • CD19 • HLA-DRB1 • PTPRC • NCAM1
|
CD8 expression • Chr del(5q) • CD4 expression
|
cyclophosphamide intravenous • fludarabine IV • mycophenolate mofetil • tacrolimus intravenous
Phase 2/3
Assiut University
Active, not recruiting
Last update posted :
05/21/2015
Initiation :
06/01/2014
Primary completion :
04/01/2015
Completion :
06/01/2015
CD8 • NCAM1 • CD4
|
CD8 expression
|
ketorolac • morphine sulphate • tramadol hydrochloride
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
04/28/2015
Initiation :
03/01/1996
CD8
|
CD8 expression
Phase 4
GlaxoSmithKline Research & Development Ltd`...
Initiation :
07/01/2013
Completion :
04/30/2014
CD8 • HLA-DRB1 • CD4 • HLA-DQA1
|
CD8 expression
|
lapatinib
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our